DARE Quote, Financials, Valuation and Earnings

Moleculin Biotech has a net margin of -17219.13% compared to Dare Bioscience's net margin of --. Dare Bioscience's return on equity of -- beat Moleculin Biotech's return on equity of --.

Dare Bioscience has a consensus price target of $13.00, signalling upside risk potential of 394.3%. On the other hand Moleculin Biotech has an analysts' consensus of $9.33 which suggests that it could grow by 2798.55%. Given that Moleculin Biotech has higher upside potential than Dare Bioscience, analysts believe Moleculin Biotech is more attractive than Dare Bioscience.

Dare Bioscience has a beta of 1.202, which suggesting that the stock is 20.169% more volatile than S&P 500. In comparison Moleculin Biotech has a beta of 1.562, suggesting its more volatile than the S&P 500 by 56.242%.

Dare Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moleculin Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dare Bioscience pays -- of its earnings as a dividend. Moleculin Biotech pays out -- of its earnings as a dividend.

Dare Bioscience quarterly revenues are $25.4K, which are larger than Moleculin Biotech quarterly revenues of --. Dare Bioscience's net income of -$4.4M is higher than Moleculin Biotech's net income of -$6.4M. Notably, Dare Bioscience's price-to-earnings ratio is -- while Moleculin Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dare Bioscience is 772.78x versus -- for Moleculin Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Macrogenics has a net margin of -17219.13% compared to Dare Bioscience's net margin of -311.07%. Dare Bioscience's return on equity of -- beat Macrogenics's return on equity of -58.23%.

Dare Bioscience has a consensus price target of $13.00, signalling upside risk potential of 394.3%. On the other hand Macrogenics has an analysts' consensus of $4.20 which suggests that it could grow by 230.71%. Given that Dare Bioscience has higher upside potential than Macrogenics, analysts believe Dare Bioscience is more attractive than Macrogenics.

Dare Bioscience has a beta of 1.202, which suggesting that the stock is 20.169% more volatile than S&P 500. In comparison Macrogenics has a beta of 1.652, suggesting its more volatile than the S&P 500 by 65.244%.

Dare Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Macrogenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dare Bioscience pays -- of its earnings as a dividend. Macrogenics pays out -- of its earnings as a dividend.

Dare Bioscience quarterly revenues are $25.4K, which are smaller than Macrogenics quarterly revenues of $13.2M. Dare Bioscience's net income of -$4.4M is higher than Macrogenics's net income of -$41M. Notably, Dare Bioscience's price-to-earnings ratio is -- while Macrogenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dare Bioscience is 772.78x versus 0.52x for Macrogenics. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of -17219.13% compared to Dare Bioscience's net margin of -271.3%. Dare Bioscience's return on equity of -- beat Spero Therapeutics's return on equity of -108.26%.

Dare Bioscience has a consensus price target of $13.00, signalling upside risk potential of 394.3%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 72.41%. Given that Dare Bioscience has higher upside potential than Spero Therapeutics, analysts believe Dare Bioscience is more attractive than Spero Therapeutics.

Dare Bioscience has a beta of 1.202, which suggesting that the stock is 20.169% more volatile than S&P 500. In comparison Spero Therapeutics has a beta of 1.313, suggesting its more volatile than the S&P 500 by 31.286%.

Dare Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dare Bioscience pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Dare Bioscience quarterly revenues are $25.4K, which are smaller than Spero Therapeutics quarterly revenues of $5.1M. Dare Bioscience's net income of -$4.4M is higher than Spero Therapeutics's net income of -$13.9M. Notably, Dare Bioscience's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dare Bioscience is 772.78x versus 5.58x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics has a net margin of -17219.13% compared to Dare Bioscience's net margin of -15.19%. Dare Bioscience's return on equity of -- beat Zevra Therapeutics's return on equity of -198.46%.

Dare Bioscience has a consensus price target of $13.00, signalling upside risk potential of 394.3%. On the other hand Zevra Therapeutics has an analysts' consensus of $21.71 which suggests that it could grow by 132.74%. Given that Dare Bioscience has higher upside potential than Zevra Therapeutics, analysts believe Dare Bioscience is more attractive than Zevra Therapeutics.

Dare Bioscience has a beta of 1.202, which suggesting that the stock is 20.169% more volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 2.011, suggesting its more volatile than the S&P 500 by 101.078%.

Dare Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dare Bioscience pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

Dare Bioscience quarterly revenues are $25.4K, which are smaller than Zevra Therapeutics quarterly revenues of $20.4M. Dare Bioscience's net income of -$4.4M is lower than Zevra Therapeutics's net income of -$3.1M. Notably, Dare Bioscience's price-to-earnings ratio is -- while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dare Bioscience is 772.78x versus 11.34x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.